Overcoming Treatment Toxicity through Sequential Therapy

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Standard

Overcoming Treatment Toxicity through Sequential Therapy. / Benada, Jan; Ejlertsen, Bent; Sørensen, Claus Storgaard.

I: Cancer Cell, Bind 35, Nr. 6, 2019, s. 821-822.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Harvard

Benada, J, Ejlertsen, B & Sørensen, CS 2019, 'Overcoming Treatment Toxicity through Sequential Therapy', Cancer Cell, bind 35, nr. 6, s. 821-822. https://doi.org/10.1016/j.ccell.2019.05.006

APA

Benada, J., Ejlertsen, B., & Sørensen, C. S. (2019). Overcoming Treatment Toxicity through Sequential Therapy. Cancer Cell, 35(6), 821-822. https://doi.org/10.1016/j.ccell.2019.05.006

Vancouver

Benada J, Ejlertsen B, Sørensen CS. Overcoming Treatment Toxicity through Sequential Therapy. Cancer Cell. 2019;35(6):821-822. https://doi.org/10.1016/j.ccell.2019.05.006

Author

Benada, Jan ; Ejlertsen, Bent ; Sørensen, Claus Storgaard. / Overcoming Treatment Toxicity through Sequential Therapy. I: Cancer Cell. 2019 ; Bind 35, Nr. 6. s. 821-822.

Bibtex

@article{044df2d3cbf6466aa147f32bc6869884,

title = "Overcoming Treatment Toxicity through Sequential Therapy",

abstract = "Combined inhibitions of PARP and DNA damage checkpoint have the potential for high anti-cancer efficacy, but concurrent inhibitions have been hampered by intolerable side effects. In this issue of Cancer Cell, Fang and colleagues (Fang et al., 2019) propose that sequential inhibitions of PARP and DNA damage checkpoint considerably widen the therapeutic window.",

author = "Jan Benada and Bent Ejlertsen and S{\o}rensen, {Claus Storgaard}",

year = "2019",

doi = "10.1016/j.ccell.2019.05.006",

language = "English",

volume = "35",

pages = "821--822",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

RIS

TY - JOUR

T1 - Overcoming Treatment Toxicity through Sequential Therapy

AU - Benada, Jan

AU - Ejlertsen, Bent

AU - Sørensen, Claus Storgaard

PY - 2019

Y1 - 2019

N2 - Combined inhibitions of PARP and DNA damage checkpoint have the potential for high anti-cancer efficacy, but concurrent inhibitions have been hampered by intolerable side effects. In this issue of Cancer Cell, Fang and colleagues (Fang et al., 2019) propose that sequential inhibitions of PARP and DNA damage checkpoint considerably widen the therapeutic window.

AB - Combined inhibitions of PARP and DNA damage checkpoint have the potential for high anti-cancer efficacy, but concurrent inhibitions have been hampered by intolerable side effects. In this issue of Cancer Cell, Fang and colleagues (Fang et al., 2019) propose that sequential inhibitions of PARP and DNA damage checkpoint considerably widen the therapeutic window.

U2 - 10.1016/j.ccell.2019.05.006

DO - 10.1016/j.ccell.2019.05.006

M3 - Journal article

C2 - 31185206

VL - 35

SP - 821

EP - 822

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -

ID: 225384566